Keros Therapeutics KROS
NASDAQ KROS
$10.00 +0.46 (+4.82%)
As of: Nov 12, 2026 · 1:02 PM EST

Keros Therapeutics (KROS) Interest & Investment Income (2026)

Updated

Analysis

Keros Therapeutics (KROS) Interest & Investment Income (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int & Inv Inc (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 186.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 67.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Keros Therapeutics 185.02 Mn -900.96 Mn - 55,000.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 55,000.00
API Access

Keros Therapeutics Interest & Investment Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=interest-and-investment-income&ticker=KROS&period=max&api_key=YOUR_API_KEY